
Opinion|Videos|June 18, 2024
Generational Trends and Innovations in Retinal Disease Treatment
A panel of ophthalmologists discuss how retinal disease management has evolved in the past decade and continues to change with advancements in diagnostics and therapies.
Advertisement
Episodes in this series
1:00 Evolving trends
5:50 Key Advances
8:20 Targeting Ang/Tie pathway
13:12 Role of steroids
15:00 Biosimilars
18:44 Therapies in the pipeline
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5


